Business
EU launch plans for ECOVAXXIN® MS
ECO Animal Health Group plc is progressing its commercial launch strategy for ECOVAXXIN® MS, a poultry vaccine against Mycoplasma synoviae, across the European Union with a phased rollout planned for 2026 and 2027. The company has secured distribution agreements covering over 220 million layer birds annually in the EU's top seven layer-producing countries, leveraging its existing commercial network for Aivlosin®. ECO expects ECOVAXXIN® MS sales to be immediately margin accretive and contribute materially to EBITDA from the 2027/2028 financial year. The launch aims to position ECO as a comprehensive Mycoplasma solutions provider, combining prevention with its treatment product, Aivlosin®. Disclaimer*
About this update from Eco Animal Health Group Plc
[{"type":"text","content":"\n\n\n\n \nECO Animal Health Group plc\n(\"ECO\" or the \"Company\")\n \nEU launch plans for ECOVAXXIN® MS\n \nECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, provides an update on its commercial launch strategy for ECOVAXXIN® MS, its poultry vaccine against Mycoplasma synoviae, across the European Union (EU).\n \nFollowing the European Commission granting marketing authorisation for ECOVAXXIN® MS, announced in December 2025, ECO's management team are progressing a detailed commercialisation plan designed to deliver strategic market entry across key European territories throughout 2026 and 2027.\n \nECOVAXXIN® MS clinical need\nECOVAXXIN® MS provides active immunisation of future layer and breeder chickens from four weeks of age, helping to reduce air-sac and foot-pad lesions and egg production losses caused by Mycoplasma synoviae infections. The infection causes economic loss, especially in laying hens, and the number of eggs produced by affected layers can be reduced by 5-10%.\n \nThe launch positions ECO as a comprehensive Mycoplasma solutions provider, combining best-in-class prevention through ECOVAXXIN® MS with market-leading treatment via its lead product Aivlosin®.\n \nGo-to-market strategy\nECO Animal Health will leverage its existing comprehensive commercial network, successfully built for Aivlosin®, for the commercialisation of ECOVAXXIN® MS, taking advantage of deep expertise and customer reach in established distribution channels, and supplementing where necessary with additional technical and geographical capabilities.\n \nThe Company has secured agreements with key strategic distribution partners providing comprehensive coverage across the EU's major poultry markets. These partnerships provide access to markets representing over 220 million layer birds annually across the EU's top seven layer-producing countries.\n \n\"This launch represents a significant milestone as the first product from ECO's proprietary R&D pipeline to be commercialised. We have developed a differentiated vaccine that addresses real producer need, with extensive technical support capabilities that have proved highly valuable to our A...